Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis.
OBJECTIVE
This study aimed to compare anti-epidermal growth factor receptor (anti-EGFR) therapy and anti-vascular endothelial growth factor therapy as first-line and second-line therapies in patients with KRAS exon 2 codon 12/13 wild-type (KRAS-WT) metastatic colorectal cancer (mCRC).


METHODS
Major databases were systematically searched. The hazard ratio (HR), odds ratio (OR), and 95% confidence intervals (95% CIs) were used to estimate the effect measures. Review Manager software version 5.3 was used for statistical analysis.


RESULTS
Seven trials including ten articles were eligible in the meta-analysis. The patients treated with anti-EGFR as first-line therapy showed a longer overall survival (OS) for KRAS-WT and all RAS wild-type (RAS-WT) mCRC (HR =0.81, 95% CI: 0.72-0.92, P<0.01, n=5; HR =0.78, 95% CI: 0.66-0.93, P<0.01, n=3, respectively). The objective response rate (ORR) was better with the anti-EGFR therapy for KRAS-WT and all RAS-WT mCRC (OR =1.32, 95% CI: 1.11-1.56, P<0.01, n=5; OR =1.55, 95% CI: 1.21-2.00, P<0.01, n=3, respectively). There was no difference in progression-free survival (PFS) for KRAS-WT mCRC and all RAS-WT mCRC between the two groups (HR =1.00; 95% CI: 0.92-1.09, P=0.99, n=4; HR =0.92, 95% CI: 0.71-1.19, P=0.52, n=3, respectively). In addition, two trials provided data on the second-line therapy; there was no significant difference in OS and PFS for the second-line therapy, but a significant improvement in ORR was found in the anti-EGFR group (OR =1.91, 95% CI: 1.16-3.16, P=0.01, n=2). No difference in the conversion therapy (OR =1.34; 95% CI: 0.91-1.99; P=0.14, n=4) was observed between the two therapies.


CONCLUSIONS
Our results indicate that anti-EGFR therapy is superior to anti-vascular endothelial growth factor therapy for OS and ORR as a first-line therapy for KRAS-WT mCRC. In the second-line therapy, there was no significant difference in the survival outcomes on the basis of OS and PFS between the two groups. However, ORR improved significantly in the anti-EGFR group.
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Hongchi
H
Wang
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Bin
B
Ma
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Peng
P
Gao
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Yongxi
Y
Song
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Qingzhou
Q
Xu
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Yaoyuan
Y
Hu
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Cong
C
Zhang
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Zhenning
Z
Wang
anti-EGFR; anti-VEGF; chemotherapy; colorectal cancer; meta-analysis